Valeant Pharmaceuticals International Inactive 10-Q2010 Q1 Quarterly report

Filed: 3 May 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: added, advisor, arrive, Aton, billion, binding, brought, CaseNo, confirmed, counter, coverage, damage, declared, Delta, derecognition, diminish, domicile, donut, Dr, exported, expressly, fade, fine, gap, Guarantor, hand, high, hole, imposed, incomplete, inRule, insignificant, Instituto, irregular, jointly, junior, Laboratoire, Ltda, MAA, Master, Merck, NM, Obama, onForm, ophthalmology, orphan, parent, PDUFA, percent, Pharma, pigmentation, plant, PPACA, predominantly, prejudice, Princeton, rank, ranking, ratable, ratably, rebate, Refissa, Renaud, single, Terapeutico, unconditionally, unsubordinated, User, validated, ValueAct, VitalScience, VPI, Xcel

Removed: abandonment, accelerated, account, achieve, acquiree, acquirer, actively, adjust, afforded, Agent, amendment, American, antibiotic, APB, appraisal, approximated, ARB, Argentina, arm, Asia, assert, Assessment, ataxia, back, backdating, baseline, began, Berlin, bifurcation, biopharmaceutical, biotechnology, blurred, borrowing, branch, built, capitalized, carryforward, categorized, category, certificate, Chancery, China, classification, collaborative, commercialization, component, conditional, confusion, consistency, consistent, constructive, contractual, coordination, Coria, correction, corroborated, credited, customer, declining, deconsolidation, deductible, deducting, demonstrated, dependent, Depending, depreciation, DermaTech, description, designated, designation, Diastat, direction, disgorgement, dismissal, dose, dual, dysarthria, earn, effort, eighteen, EITF, eliminated, emerging, endpoint, enhanced, enriched, Epileptology, equivalent, escrow, estimable, estimation, evaluated, event, exact, exceed, exceeded, exchanging, exclude, executing, execution, exhibit, exit, expanded, expensed, extension, extinguished, FAS, fatigue, fiduciary, floating, Force, forfeiture, framework, frequency, function, funded, generating, Germany, government, greater, hedged, hedging, highest, highly, Hong, identifiable, IIa, impacted, impairment, implementation, important, imposition, improve, improvement, incorporation, individual, Indonesia, initiating, injunction, input, insufficient, intellectual, interferon, Intranasal, invaluable, inventory, Invida, issuer, ITT, Japan, Kong, Korea, large, largely, life, limitation, longer, Macau, maintenance, Malaysia, manner, mature, measuring, median, meeting, merit, met, methodology, mg, minimize, mismanagement, month, monthly, muscle, nausea, neuralgia, neuropathic, nominal, noncontrolling, nonconvertible, nonrecurring, objective, occur, orderly, organizational, outlicensed, ownership, pain, paper, Participating, partnering, partnership, pegylated, pension, Periodic, permanent, pertain, placebo, plaintiff, planned, preferred, preliminary, previously, prioritized, profitability, prohibition, property, proportion, proprietary, Protocol, Pte, purported, qualify, randomized, ratified, realigned, realization, recognizing, Reconciliation, reconsidering, regional, removed, renewal, represent, repricing, rescission, reserve, responder, Restated, RESTORE, retention, retrospective, revised, Roche, scientific, scope, Seattle, secure, seizure, shareholder, Sherwood, shipment, shipped, side, Singapore, slurring, Society, somnolence, specific, speech, spending, stable, stage, statistically, staying, stockholder, streamline, subjective, submission, subsequent, successful, sufficiency, suit, suspending, suspension, sustained, swap, Taiwan, target, Task, taxable, technology, Thailand, tolerability, traded, tremor, trust, trustee, turnover, Tyson, unjustly, upgrade, Uruguay, utilized, vary, vesting, Vietnam, vigorously, visibility, vision, Washington, waste, weight, weighted, withdrew, yearly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Valeant Pharmaceuticals International similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 15.1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of Valeant Pharmaceuticals International:

We have reviewed the accompanying condensed consolidated balance sheet of Valeant Pharmaceuticals International (the “Company”) and its subsidiaries as of March 31, 2010, and the related condensed consolidated statements of operations and the condensed consolidated statements of comprehensive income, for the three-month periods ended March 31, 2010 and 2009 and the condensed consolidated statements of cash flows for the three-month periods ended March 31, 2010 and 2009. These interim financial statements are the responsibility of the Company’s management.

We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the accompanying condensed consolidated interim financial statements for them to be in conformity with accounting principles generally accepted in the United States of America.

We previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet as of December 31, 2009, and the related consolidated statements of operations, of stockholders’ equity, and of cash flows for the year then ended (not presented herein), and in our report dated February 23, 2010, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2009, is fairly stated in all material respects in relation to the consolidated balance sheet from which it has been derived.

/s/ PricewaterhouseCoopers LLP

Orange County, California

May 3, 2010